Trial of three drugs plus temodar - Revision history

Lazy at 08:17, 18 January 2025

2025-01-18T08:17:55Z

← Older revision		Revision as of 01:17, 18 January 2025
Line 14:		Line 14:
	\|toxicity_level=4		\|toxicity_level=4
	\|toxicity_explanation=The toxicity level of this treatment is relatively high because it involves a combination of drugs repurposed for different conditions with Temodar, a chemotherapy drug used to treat brain tumors. While the exact toxicity can vary based on the specific combination, the potential for increased toxicity from the chemotherapy component remains a significant risk. This toxicity can result in side effects ranging from mild symptoms such as nausea and fatigue, to more severe ones like infections or bleeding. However, in some cases, the potential benefits, like potentially longer survival periods, may outweigh these risks. It should be noted that the safety and efficacy of these combinations are still under investigation, and results to date have been mixed.		\|toxicity_explanation=The toxicity level of this treatment is relatively high because it involves a combination of drugs repurposed for different conditions with Temodar, a chemotherapy drug used to treat brain tumors. While the exact toxicity can vary based on the specific combination, the potential for increased toxicity from the chemotherapy component remains a significant risk. This toxicity can result in side effects ranging from mild symptoms such as nausea and fatigue, to more severe ones like infections or bleeding. However, in some cases, the potential benefits, like potentially longer survival periods, may outweigh these risks. It should be noted that the safety and efficacy of these combinations are still under investigation, and results to date have been mixed.
	}}		\|overview=The combination of repurposed drugs with Temodar is being investigated for glioblastoma treatment in Phase 1 and Phase 2 trials, showing mixed results in improving survival compared to standard treatment, with a median survival ranging from 16.1 months to 29.6 months depending on the combination. While the approach aims to target multiple growth pathways simultaneously, it carries a relatively high toxicity level, necessitating careful consideration of potential benefits versus risks.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:25:45Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:25, 12 November 2024
Line 10:		Line 10:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Early clinical trials exploring combinations of repurposed drugs with Temodar for glioblastoma treatment have yielded mixed results. Some combinations have shown potential for improving outcomes, while others have not demonstrated significant benefits over standard treatment. The CUSP9 protocol introduces a conceptually new approach by targeting multiple growth pathways simultaneously with a cocktail of repurposed drugs plus metronomic Temodar, highlighting the importance of simultaneous pathway inhibition for treatment efficacy.		\|notes=Early clinical trials exploring combinations of repurposed drugs with Temodar for glioblastoma treatment have yielded mixed results. Some combinations have shown potential for improving outcomes, while others have not demonstrated significant benefits over standard treatment. The CUSP9 protocol introduces a conceptually new approach by targeting multiple growth pathways simultaneously with a cocktail of repurposed drugs plus metronomic Temodar, highlighting the importance of simultaneous pathway inhibition for treatment efficacy.
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|links=		\|links=
	\|toxicity_level=4		\|toxicity_level=4
	\|toxicity_explanation=The toxicity level of this treatment is relatively high because it involves a combination of drugs repurposed for different conditions with Temodar, a chemotherapy drug used to treat brain tumors. While the exact toxicity can vary based on the specific combination, the potential for increased toxicity from the chemotherapy component remains a significant risk. This toxicity can result in side effects ranging from mild symptoms such as nausea and fatigue, to more severe ones like infections or bleeding. However, in some cases, the potential benefits, like potentially longer survival periods, may outweigh these risks. It should be noted that the safety and efficacy of these combinations are still under investigation, and results to date have been mixed.		\|toxicity_explanation=The toxicity level of this treatment is relatively high because it involves a combination of drugs repurposed for different conditions with Temodar, a chemotherapy drug used to treat brain tumors. While the exact toxicity can vary based on the specific combination, the potential for increased toxicity from the chemotherapy component remains a significant risk. This toxicity can result in side effects ranging from mild symptoms such as nausea and fatigue, to more severe ones like infections or bleeding. However, in some cases, the potential benefits, like potentially longer survival periods, may outweigh these risks. It should be noted that the safety and efficacy of these combinations are still under investigation, and results to date have been mixed.
	}}		}}

Lazy at 16:53, 27 March 2024

2024-03-27T16:53:35Z

← Older revision		Revision as of 09:53, 27 March 2024
Line 12:		Line 12:
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
	\|links=		\|links=
			\|toxicity_level=4
			\|toxicity_explanation=The toxicity level of this treatment is relatively high because it involves a combination of drugs repurposed for different conditions with Temodar, a chemotherapy drug used to treat brain tumors. While the exact toxicity can vary based on the specific combination, the potential for increased toxicity from the chemotherapy component remains a significant risk. This toxicity can result in side effects ranging from mild symptoms such as nausea and fatigue, to more severe ones like infections or bleeding. However, in some cases, the potential benefits, like potentially longer survival periods, may outweigh these risks. It should be noted that the safety and efficacy of these combinations are still under investigation, and results to date have been mixed.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Combination of Repurposed Drugs plus Temodar |FDA_approval=Varies (individual drugs have separate FDA approvals for other conditions) |used_for=Investigational use in glioblastoma |clinical_trial_phase=Phase 1 and Phase 2 trials |common_side_effects=Varies based on the combination; potential for increased chemotherapy toxicity |OS_without=Standard treatment: median survival of 16.1 months |OS_with=Varies; one combination showed median survival..."

2024-03-20T13:04:45Z

Created page with "{{TreatmentInfo |drug_name=Combination of Repurposed Drugs plus Temodar |FDA_approval=Varies (individual drugs have separate FDA approvals for other conditions) |used_for=Investigational use in glioblastoma |clinical_trial_phase=Phase 1 and Phase 2 trials |common_side_effects=Varies based on the combination; potential for increased chemotherapy toxicity |OS_without=Standard treatment: median survival of 16.1 months |OS_with=Varies; one combination showed median survival..."

New page

{{TreatmentInfo
|drug_name=Combination of Repurposed Drugs plus Temodar
|FDA_approval=Varies (individual drugs have separate FDA approvals for other conditions)
|used_for=Investigational use in glioblastoma
|clinical_trial_phase=Phase 1 and Phase 2 trials
|common_side_effects=Varies based on the combination; potential for increased chemotherapy toxicity
|OS_without=Standard treatment: median survival of 16.1 months
|OS_with=Varies; one combination showed median survival of 20 months, another study reported median survival up to 29.6 months with high-dose Valproic Acid
|PFS_with=Study-specific; one phase 2 trial reported no significant difference in PFS with the addition of celecoxib
|usefulness_rating=3
|notes=Early clinical trials exploring combinations of repurposed drugs with Temodar for glioblastoma treatment have yielded mixed results. Some combinations have shown potential for improving outcomes, while others have not demonstrated significant benefits over standard treatment. The CUSP9 protocol introduces a conceptually new approach by targeting multiple growth pathways simultaneously with a cocktail of repurposed drugs plus metronomic Temodar, highlighting the importance of simultaneous pathway inhibition for treatment efficacy.
|category=Repurposed Drugs
|links=
}}